- [TERAPIA GÉNICA Y REGULACIÓN DE LA EXPRESIÓN GÉNICA]
- [TERAPIA GÉNICA DE ENFERMEDADES CONGÉNITAS CON AFECTACIÓN NEUROLÓGICA]
Early sirtuin 2 inhibition prevents age-related cognitive decline in a senescence-accelerated mouse model
Teresa Diaz-Perdigon, Francisco B Belloch, Ana Ricobaraza, Elghareeb E Elboray, Takayoshi Suzuki, Rosa M Tordera, Elena Puerta
The senescence-accelerated mouse prone-8 (SAMP8) model has been considered as a good model for aged-related cognitive decline and Alzheimer's disease (AD). Since epigenetic alterations represent a crucial mechanism during aging, in the present study we tested whether the inhibition of the histone deacetylase sirtuin 2 (SIRT2) could ameliorate the age-dependent cognitive impairments and associated neuropathology shown by SAMP8 mice.
To this end, the potent SIRT2-selective inhibitor, 33i (5 mg/kg i.p. 8 weeks) was administered to 5-month-old (early treatment) and 8-month-old (late treatment) SAMP8 and aged matched control, senescence-accelerated mouse resistant-1 (SAMR1) mice. 33i administration to 5-month-old SAMP8 mice improved spatial learning and memory impairments shown by this strain in the Morris water maze. SAMP8 showed hyperphosphorylation of tau protein and decrease levels of SIRT1 in the hippocampus, which were not altered by 33i treatment.
However, this treatment upregulated the glutamate receptor subunits GluN2A, GluN2B, and GluA1 in both SAMR1 and SAMP8. Moreover, early SIRT2 inhibition prevented neuroinflammation evidenced by reduced levels of GFAP, IL-1β, Il-6, and Tnf-α, providing a plausible explanation for the improvement of cognitive deficits shown by 33i-treated SAMP8 mice. When 33i was administered to 8-month-old SAMP8 with a severe established pathology, increases in GluN2A, GluN2B, and GluA1 were observed; however, it was not able to reverse the cognitive decline or the neuroinflammation.
These results suggest that early SIRT2 inhibition might be beneficial in preventing age-related cognitive deficits, neuroinflammation, and AD progression and could be an emerging candidate for the treatment of other diseases linked to dementia.
CITA DEL ARTÍCULO Neuropsychopharmacology. 2020 Jan;45(2):347-357. doi: 10.1038/s41386-019-0503-8. Epub 2019 Aug 30.